

RESOURCES

PEOPLE

ExonHit Therapeutics (Paris) has announced the appointments of **Florence Abrahamian** as financial director, **Jim Liddy** as vice president, business development, and **Aram Mangasarian** as director of business development. Ms. Abrahamian joins the company from the Paribas Group, where she held posts in the department of asset management and private banking; Mr. Liddy was previously at AlphaGene; and Dr. Mangasarian comes to ExonHit from the University of Geneva School of Medicine.

Alexander Chucholowski has been appointed senior director of chemistry, and **Cheryl Lawton** has been appointed senior vice president of Boston operations and general counsel of Anadys Pharmaceuticals (San Diego, CA). Dr. Chucholowski joins Anadys from Hoffmann-La Roche, where he served most recently as head of the automated chemistry department. Ms. Lawton was previously general counsel and vice president of administration at Creative BioMolecules.

Kieran T. Gallahue has been appointed president of Nanogen (San Diego, CA). He will retain his current title of CFO until a replacement CFO is appointed. Former president **Howard C. Birndorf** will continue to hold the titles of chairman and CEO.

Aviron (Mountain View, CA) has named **Harry B. Greenberg** senior vice president, R&D, and chief scientific officer. For the past 17 years, Dr. Greenberg has been on the faculty of the Stanford University School of Medicine, most recently as senior associate dean for research and the Joseph D. Grant endowed professor of medicine.

George Schreiner has been promoted to chief scientific officer of Scios (Sunnyvale, CA). He was previously vice president, cardiorenal research. The company also announced the promotion of **Darlene Horton** to vice president, medical affairs. She has been at Scios since 1996, most recently serving as senior director, clinical research and clinical information systems.

Variagenics (Cambridge, MA) has announced the appointment of **Alan C. Houston** as chief medical officer and vice president of clinical development. Most recently, Dr. Houston was vice president of Quintiles Transnational's worldwide phase I services division.

Seattle Genetics (Bothell, WA) has named **Marc Lippman**, director of the Lombardi Cancer Research Center at Georgetown

University Medical School, to its board of directors. The company also named **Tim Carroll** as CFO. Mr. Carroll was most recently vice president of finance and CFO of Aris Corp.

Genomics Collaborative has announced the promotion of **Michael J. Pellini** to CEO from chief operating officer. Dr. Pellini joined the company in July 1999 as vice president of business development. Additionally, the company announced the following new hires: **Brent Richter** as director of bioinformatics; **Patricia A. Schreck** as general counsel; **Art Williams** as chief information officer; and **Kristin Ardlie** as vice president of genetics.

David E. Riggs has been named senior vice president and CFO of Axy's Pharmaceuticals (S. San Francisco, CA). He joins the company from Unimed Pharmaceuticals, where he served as senior vice president, business operations. Axy's also announced the appointment of **Michael J. Green** as vice president of medicinal chemistry. Dr. Green was previously vice president of Trega Biosciences' drug discovery division.



Martin Soeters has been appointed president of Novo Nordisk Pharmaceuticals (Princeton, NJ) and head of Novo Nordisk's North American region. He joined the company in 1980, and has been senior vice president, marketing since 1998.

Aradigm (Hayward, CA) has announced the appointment of **Richard P. Thompson** as chairman of the board, in addition to his role as president and CEO. Mr. Thompson joined Aradigm in 1994. The company has also promoted **Igor Gonda** from vice president of R&D to chief scientific officer, and **Stephen Farr** from vice president, pharmaceutical sciences to vice president of R&D.

Rigel Pharmaceuticals (S. San Francisco, CA) has named **Thomas S. Volpe** to its board of directors, bringing its total number of members to seven. Mr. Volpe is chairman of Prudential Volpe Technology Group, and for 12 years, was president, CEO, and founder of Volpe Brown Whelan & Company.

James W. Young, CEO of Sunesis Pharmaceuticals, has been elected to the board of directors of Corixa (Seattle, WA). Dr. Young will occupy the board position left vacant by the departure of **Andrew Senyei**.